How Often Is Reclast Given? Dosing by Condition

Reclast (zoledronic acid) is given as a single intravenous infusion once a year for osteoporosis and as a single one-time infusion for Paget’s disease of bone. The 5 mg dose stays the same across conditions, but the expected number of infusions and the possibility of a treatment pause afterward differ depending on why you’re receiving it. The schedule is straightforward on the surface, yet several factors can shift the timing in practice.

Once a Year for Osteoporosis

For postmenopausal osteoporosis, Reclast is infused intravenously once every twelve months. The drug has an unusually long residence time in bone tissue, which is what makes annual dosing feasible. In the large HORIZON trial, this once-yearly schedule reduced the risk of new vertebral fractures by about 70% and hip fractures by roughly 40%, while increasing bone mineral density at the spine and hip significantly over three years.¹ That long duration of action, driven by the drug’s strong binding affinity to bone mineral, is also what opens the door to treatment pauses down the line.²

The same annual 5 mg infusion is approved for osteoporosis in men.³ It is also used on the same schedule for glucocorticoid-induced osteoporosis, the bone loss that can develop when someone takes corticosteroids like prednisone for an extended period. In all three osteoporosis indications the dose and frequency are identical: 5 mg, IV, once a year.

A Single Infusion for Paget’s Disease

Paget’s disease of bone is a different situation entirely. This condition involves localized areas of excessive bone remodeling, and a single 5 mg infusion of Reclast is often the only treatment needed. In a Belgian registry study of patients treated in routine clinical practice, response rates after one infusion were above 90% at one, two, and three years.⁴ About one in five patients did relapse over that three-year window, with a median time to relapse of around 21 months, but most of those who relapsed regained remission by the end of the observation period.

When retreatment is needed, it works. A small open-label study of patients who relapsed after their initial zoledronic acid infusion found that a second dose brought their bone-turnover markers back down to the same levels they had reached after the first dose, with no sign of treatment resistance.⁵ The takeaway for Paget’s patients is that you receive one infusion and then wait, monitoring blood markers periodically. A second infusion comes only if the disease flares again, and that may never happen.

How Long Should You Keep Getting Annual Infusions for Osteoporosis?

This is the question your doctor is weighing carefully. Because Reclast binds tightly to bone and releases slowly over years, a treatment pause (sometimes called a “drug holiday”) is an option after an initial course. The HORIZON extension trial randomized women who had received three annual infusions to either continue for three more years or switch to placebo. Women who stopped treatment maintained bone density well above their pretreatment levels for the next three years, and bone-turnover markers stayed suppressed, though they did creep upward slightly. The group that continued for six years kept slightly higher bone density and had fewer new vertebral fractures, but for other fracture types the difference was not significant.⁶

What this means in practice: after three years of annual Reclast, many patients can pause treatment for up to three years. Current guidance supports continuing treatment beyond three years primarily for people who remain at high risk, such as those with a bone density T-score still below −2.5 or those who have already had a vertebral fracture.⁷ If you’re at lower risk after three infusions, pausing and reassessing bone density periodically is reasonable. The optimal length of a holiday hasn’t been nailed down, but the data so far suggest up to three years off Reclast is safe for many people, with a decision to restart based on new bone density scans and fracture risk assessment.

What Happens on Infusion Day

Reclast is given as an IV infusion over at least 15 minutes in most protocols, though some clinics extend this to 30 minutes or longer, particularly for patients with borderline kidney function. You’ll typically receive it in a clinic, infusion center, or doctor’s office. Before the infusion, a blood draw confirms your kidney function is adequate and that your calcium and vitamin D levels are in range. Most providers will want you to be well hydrated beforehand and may give you a bag of saline before or alongside the drug.

The most common side effect is a flu-like reaction in the first one to three days after infusion: fever, muscle aches, headache, and fatigue. This acute-phase reaction is most pronounced after the first infusion and tends to be milder or absent with subsequent annual doses. Taking acetaminophen or ibuprofen around the time of the infusion helps, and your doctor may recommend it proactively.

Kidney Function Thresholds

Reclast is cleared through the kidneys, and reduced kidney function raises the risk of acute kidney injury after the infusion. Regulatory guidance in the UK recommends using creatinine clearance rather than estimated glomerular filtration rate (eGFR) when assessing eligibility, and advises against giving the infusion if creatinine clearance falls below 35 mL/min. In a real-world analysis, when patients with creatinine clearance below that cutoff did receive the infusion, acute kidney injury occurred in a small fraction, roughly 3% of cases with available follow-up. The same study suggested that slowing the infusion to 30 minutes for patients with an eGFR below 50 may add a margin of safety.⁸

If your kidney function is borderline, your doctor may choose a different osteoporosis treatment altogether. Denosumab, a subcutaneous injection given every six months, is one common alternative for people whose kidneys can’t safely handle Reclast. The kidney check matters every time you’re due for an infusion, not just the first time, because kidney function can change from year to year.

Rare but Serious Risks Over Multiple Doses

Two uncommon complications get the most attention with prolonged bisphosphonate use: osteonecrosis of the jaw and atypical femur fractures. Both are rare at the doses and frequencies used for osteoporosis, but they’re worth understanding because they factor into decisions about how long to continue treatment.

Osteonecrosis of the jaw is an area of exposed bone in the mouth that fails to heal normally. In a pooled analysis of over 5,900 patients who received zoledronic acid across five clinical trials, the incidence was less than one case per 14,200 patient-treatment-years.⁹ A French pharmacovigilance database analysis spanning 2011 to 2020 reported a slightly higher real-world rate of roughly 10 cases per 100,000 patient-years with zoledronate, compared to about 5 per 100,000 with alendronate (the most common daily or weekly oral bisphosphonate). Recent dental work appeared in over 40% of the jaw osteonecrosis cases, which is why dentists and doctors often coordinate timing: ideally, invasive dental procedures happen before an infusion, not right after.¹⁰

Atypical femur fractures are stress fractures that occur along the shaft of the thighbone rather than at the hip, and they are linked to long-term bisphosphonate use. In a large study of nearly 200,000 women, the risk rose steeply with duration of use: compared to minimal exposure, risk was roughly nine times higher at three to five years, and over 40 times higher at eight or more years of bisphosphonate therapy. The reassuring finding is that the risk drops quickly once the drug is stopped.¹¹ This steep duration-dependent risk is a major reason clinicians recommend drug holidays rather than indefinite annual infusions. For most patients, the fracture-prevention benefits of Reclast far outweigh these risks over a three-year treatment course, but the balance shifts the longer therapy continues without a break.

The Atrial Fibrillation Signal

The original HORIZON trial flagged a possible link between zoledronic acid and atrial fibrillation, and the question has been debated ever since. A meta-analysis and systematic review of trials in primary osteoporosis found that overall cardiovascular events were modestly higher with zoledronic acid compared to placebo, driven mainly by an increased risk of arrhythmias rather than heart attacks or heart failure. Atrial fibrillation specifically showed a trend toward higher risk, though it fell just short of conventional statistical significance.¹²

A propensity-matched study comparing zoledronic acid to denosumab found that the zoledronic acid group had a modestly higher rate of atrial fibrillation over one year in osteoporosis patients.¹³ And in a separate cohort study of older cancer patients receiving IV bisphosphonates (often at higher and more frequent doses than the osteoporosis schedule), the risk of atrial fibrillation was about 30% higher than in non-users.¹⁴

What does this mean for you? The absolute risk increase is small. If you have no history of heart rhythm problems, this is generally not a reason to avoid Reclast. If you already have atrial fibrillation or are at elevated risk for it, it’s worth discussing with your doctor whether an alternative like denosumab makes more sense.

Why the Once-a-Year Schedule Matters for Adherence

Osteoporosis is a condition where people commonly stop treatment too early. Daily or weekly oral bisphosphonates have notoriously poor adherence: they must be taken on an empty stomach, with a full glass of water, while staying upright for at least 30 minutes. Many patients abandon the regimen within a year. Reclast sidesteps that problem entirely. You show up once a year, sit for 15 to 30 minutes, and you’re done. A review of adherence studies found that the once-yearly schedule was clearly preferred by patients and that compliance was higher with zoledronic acid than with oral bisphosphonates, though the evidence base remains limited.¹⁵ For a disease that requires years of treatment to yield its full fracture-prevention benefit, the convenience of one annual visit is a genuine clinical advantage.

Switching To or From Reclast

If you’ve been on an oral bisphosphonate and are switching to Reclast, the transition is generally straightforward. You stop the oral medication and receive your first infusion when the next dose would have been due. There’s no washout period needed because the drugs share the same mechanism.

Switching from denosumab to Reclast is a more delicate maneuver. Denosumab works by blocking a different pathway in bone remodeling, and when you stop it, there’s a rebound effect: bone turnover surges well above baseline, and bone density can drop rapidly. In some patients, this rebound has been associated with multiple vertebral fractures.¹⁶ For this reason, people coming off denosumab are typically transitioned to a bisphosphonate like Reclast to consolidate the bone gains and prevent that rebound. The timing matters: the Reclast infusion is usually given around six months after the last denosumab injection, when the next denosumab dose would have been due, to minimize any gap in bone protection.

Going in the other direction, from Reclast to denosumab, is less fraught because bisphosphonates don’t produce a rebound when stopped. Some patients switch because of kidney function changes that make Reclast less suitable, or because they prefer the convenience of a home-administered subcutaneous injection every six months.

Preparing for Your First Infusion

If you’ve been prescribed Reclast and are approaching your first infusion, a few practical points are worth knowing. Make sure you’re taking adequate calcium and vitamin D in the weeks leading up to the infusion, because low calcium levels can cause the drug to pull too much calcium from the blood. Your provider should check a blood calcium level and kidney function beforehand. If you have any dental work pending, especially extractions or implants, try to get it completed before the infusion rather than scheduling it shortly afterward. Drink plenty of water the day before and the day of the infusion.

Plan for the possibility of feeling achy and feverish for a day or two afterward. Most people feel fine by day three. Having acetaminophen on hand is a good idea. If you tolerate the first infusion well, subsequent annual infusions tend to be easier, as the acute-phase reaction weakens with each dose. And if the annual cadence of infusions sounds appealing compared to the daily pill routine, it’s worth knowing that after three infusions you and your doctor will reassess whether to continue, take a break, or change course depending on how your bone density and fracture risk look at that point.